Skip to content

Ketamine: all studies

Page 141 of 449: studies 1,401 to 1,410 of 4,486, newest first. Back to the ketamine overview

Research

Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression.

Journal of Psychopharmacology April 1, 2024 Nelson B Rodrigues, David C J Chen-Li, Joshua D. Di Vincenzo et al. 12 citations

Converging lines of evidence indicate that ketamine is a rapid antidepressant for individuals with treatment-resistant depression. Hitherto, no reliable a priori predictors of ketamine response have been reported. Pharmacogenetic biomarkers have yielded mixed results regarding potential candidate genes associated with ketamine's biochemistry as reliable predictors of response. No studies have...

Low-dose ketamine safely reduces acute pain in the ED with a more rapid and shorter effect than morphine.

Annals of Internal Medicine April 1, 2024 Evan S Schwarz

Guo J, Zhao F, Bian J, et al. Low-dose ketamine versus morphine in the treatment of acute pain in the emergency department: a meta-analysis of 15 randomized controlled trials. Am J Emerg Med. 2024;76:140-149. 38071883.

DOI: 10.7326/J24-0017 (opens in new tab) Full text (opens in new tab) Pain management Emergency medicine Ketamine therapy Analgesics +1

Acute Dissociation and Ketamine's Antidepressant and Anti-Suicidal Ideation Effects in a Midazolam-Controlled Trial.

The International Journal of Neuropsychopharmacology April 1, 2024 Sumra Sajid, Hanga C Galfalvy, John G Keilp et al. 9 citations

We sought to explore relationships of acute dissociative effects of intravenous ketamine with change in depression and suicidal ideation and with plasma metabolite levels in a randomized, midazolam-controlled trial. Data from a completed trial in suicidal, depressed participants (n = 40) randomly assigned to ketamine was used to examine relationships between ketamine treatment-emergent...

DOI: 10.1093/ijnp/pyae017 (opens in new tab) Full text (opens in new tab) Dissociation Plasma metabolite Suicidal ideation Ketamine therapy +3

Ketamine Infusion in a Resistant Obsessive-Compulsive Disorder Patient in Bangladesh with Severe Suicidal Ideation: A Case Report.

Cureus April 1, 2024 Sultana Algin, Debasish Banik, Sm Atikur Rahman et al. 1 citation

Treatment of resistant obsessive-compulsive disorder (OCD) typically results in insufficient symptom alleviation, and even long-term medication often fails to have the intended effect. Ketamine is a potent non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. Studies have shown that low-dose ketamine infusion results in a considerable reduction in obsessive-compulsive symptoms...

Potentiation of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus.

Expert Opinion on Therapeutic Targets April 1, 2024 Carlos Arrabal-Gómez, Pedro Serrano-Castro, Jose Andrés Sánchez-Pérez et al. 7 citations

Major Depressive Disorder (MDD) poses a significant challenge to global health, with current treatments often limited by efficacy and onset delays. This study explores the synergistic antidepressant-like effects of an NPY1R agonist and Ketamine, targeting their neurobiological interactions within the ventral hippocampus. Utilizing a preclinical model, this study administered Neuropeptide Y...

DOI: 10.1080/14728222.2024.2342524 (opens in new tab) Full text (opens in new tab) Neurogenesis Antidepressant therapy Npy1r agonist Ventral hippocampus +9

Very Low-Dose Sublingual Ketamine for Borderline Personality Disorder and Treatment-Resistant Depression.

Cureus April 1, 2024 Mitchell B. Liester, Rachel Wilkenson, Barry Patterson et al. 3 citations

Borderline personality disorder (BPD) and treatment-resistant depression (TRD) are common mental disorders that are challenging to treat. Ketamine is an N-methyl-D-aspartate receptor antagonist that has shown promise as a rapid-acting antidepressant when administered intravenously. BPD symptoms have also been demonstrated to improve with repeated intravenous administration of ketamine, and a...

DOI: 10.7759/cureus.57654 (opens in new tab) Full text (opens in new tab) Ampa receptor Brain-derived neurotrophic factor Glutamate dysregulation Low dose ketamine +6

From Wheelchair Bound to Working: A Case Study of Intravenous Ketamine Infusions in Treating Stiff Person Syndrome.

Cureus April 1, 2024 Ashraf F Hanna, Danielle Bolling, Mariam Tadros 3 citations

Stiff Person Syndrome (SPS) is a rare autoimmune condition marked by extremely painful muscle spasms, stiffness, and rigidity throughout the body. Its rarity often translates to limited treatment options for patients and, occasionally, challenges in obtaining a definitive diagnosis. SPS also impacts patients' mental health, social and economic involvement, and overall quality of life. A...

DOI: 10.7759/cureus.59397 (opens in new tab) Full text (opens in new tab) Chronic pain Intravenous ketamine Ketamine hydrochloride Pain management +5

Effects of New Psychoactive Substance Esketamine on Behaviors and Transcription of Genes in Dopamine and GABA Pathways in Zebrafish Larvae.

Bulletin of environmental contamination and toxicology March 31, 2024 Si-Ying Li, Wen-Jun Shi, Dong-Dong Ma et al. 9 citations

Esketamine (ESK) is the S-enantiomer of ketamine racemate (a new psychoactive substance) that can result in illusions, and alter hearing, vision, and proprioception in human and mouse. Up to now, the neurotoxicity caused by ESK at environmental level in fish is still unclear. This work studied the effects of ESK on behaviors and transcriptions of genes in dopamine and GABA pathways in zebrafish...

Ketamine and epigenetic processes in depression, intersection between serotonergic and glutamatergic pathways

Journal of Psychedelic Studies March 29, 2024 Arghavan Nepton, Hesam Farahani, Monnica T. Williams et al. 2 citations

Abstract Background Hypotheses surrounding the etiology of depressive disorders encompass a wide range of biological changes that can occur in a depressed individual, from gene variations to epigenetic modifications and not only serotonergic mechanisms. Once again, the therapy response of the patient to antidepressants is connected to modifications in the epigenetic regulation of genes within...

Comparative brain-wide mapping of ketamine- and isoflurane-activated nuclei and functional networks in the mouse brain.

Elife March 21, 2024 Yue Hu, Wenjie Du, Jiangtao Qi et al. 27 citations

Ketamine (KET) and isoflurane (ISO) are two widely used general anesthetics, yet their distinct and shared neurophysiological mechanisms remain elusive. In this study, we conducted a comparative analysis of the effects of KET and ISO on c-Fos expression across the mouse brain, utilizing hierarchical clustering and c-Fos-based functional network analysis to evaluate the responses of individual...